메뉴 건너뛰기




Volumn 7, Issue 1, 2015, Pages

A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLICLAZIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; METFORMIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; VILDAGLIPTIN;

EID: 84937037763     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/s13098-015-0058-8     Document Type: Article
Times cited : (9)

References (37)
  • 1
    • 2342466734 scopus 로고    scopus 로고
    • Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030
    • 15111519
    • Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.
    • (2004) Diabetes Care , vol.27 , Issue.5 , pp. 1047-1053
    • Wild, S.1    Roglic, G.2    Green, A.3    Sicree, R.4    King, H.5
  • 2
    • 84881589345 scopus 로고    scopus 로고
    • Secular changes in the age-specific prevalence of diabetes among U.S. adults: 1988-2010
    • 3747941 23637354
    • Cheng YJ, Imperatore G, Geiss LS, Wang J, Saydah SH, Cowie CC, et al. Secular changes in the age-specific prevalence of diabetes among U.S. adults: 1988-2010. Diabetes Care. 2013;36:2690-6.
    • (2013) Diabetes Care , vol.36 , pp. 2690-2696
    • Cheng, Y.J.1    Imperatore, G.2    Geiss, L.S.3    Wang, J.4    Saydah, S.H.5    Cowie, C.C.6
  • 3
    • 33846083971 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association
    • 17192512
    • Buse JB, Gisnberg HN, Baknis GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular disease in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-26.
    • (2007) Circulation , vol.115 , pp. 114-126
    • Buse, J.B.1    Gisnberg, H.N.2    Baknis, G.L.3    Clark, N.G.4    Costa, F.5    Eckel, R.6
  • 4
    • 77952968331 scopus 로고    scopus 로고
    • Diabetes and coronary heart disease as a risk factors for mortality in old adults
    • 3145803 20569763
    • Carnethon MR, Biggs ML, Barzilay J, Kuller LH, Mozaffarian D, Mukamal K, et al. Diabetes and coronary heart disease as a risk factors for mortality in old adults. Am J Med. 2010;123(6):556. e1-9.
    • (2010) Am J Med , vol.123 , Issue.6 , pp. 556. e1-9
    • Carnethon, M.R.1    Biggs, M.L.2    Barzilay, J.3    Kuller, L.H.4    Mozaffarian, D.5    Mukamal, K.6
  • 5
    • 65349085059 scopus 로고    scopus 로고
    • Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framinghan Heart study, 1950 to 2005
    • 2789419 19307472
    • Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino Sr RB, Savage PJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framinghan Heart study, 1950 to 2005. Circulation. 2009;119:1728-35.
    • (2009) Circulation , vol.119 , pp. 1728-1735
    • Preis, S.R.1    Hwang, S.J.2    Coady, S.3    Pencina, M.J.4    D'Agostino, R.B.5    Savage, P.J.6
  • 6
    • 67651097482 scopus 로고    scopus 로고
    • Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framinghan Heart study
    • 2789428 19581493
    • Preis SR, Pencina MJ, Hwang SJ, D'Agostino Sr RB, Savage PJ, Levy D, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framinghan Heart study. Circulation. 2009;120:212-20.
    • (2009) Circulation , vol.120 , pp. 212-220
    • Preis, S.R.1    Pencina, M.J.2    Hwang, S.J.3    D'Agostino, R.B.4    Savage, P.J.5    Levy, D.6
  • 7
    • 0035856980 scopus 로고    scopus 로고
    • Biochemistry and molecular cell biology of diabetic complications
    • 1:CAS:528:DC%2BD38Xhtlyltg%3D%3D 11742414
    • Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.
    • (2001) Nature , vol.414 , pp. 813-820
    • Brownlee, M.1
  • 8
    • 33645745733 scopus 로고    scopus 로고
    • Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes
    • 1:CAS:528:DC%2BD28XjsVequ7k%3D 16609090
    • Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681-7.
    • (2006) JAMA , vol.295 , pp. 1681-1687
    • Monnier, L.1    Mas, E.2    Ginet, C.3    Michel, F.4    Villon, L.5    Cristol, J.P.6
  • 9
    • 84910110212 scopus 로고    scopus 로고
    • The insulin resistance syndrome: Impact on lipoprotein metabolism and atherothrombosis
    • 1:STN:280:DC%2BD3M7hsVChtg%3D%3D 11143762
    • Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk. 2000;7:325-31.
    • (2000) J Cardiovasc Risk , vol.7 , pp. 325-331
    • Ginsberg, H.N.1    Huang, L.S.2
  • 10
    • 0037338257 scopus 로고    scopus 로고
    • Differential selectivity of insulin secretagogues: Mechanisms, clinical implications, and drug interactions
    • 12623163
    • Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications. 2003;17:11-5.
    • (2003) J Diabetes Complications , vol.17 , pp. 11-15
    • Gribble, F.M.1    Reimann, F.2
  • 11
    • 77951758117 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus
    • 1:CAS:528:DC%2BC3cXntVantL8%3D 20411998
    • Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2010;30:463-84.
    • (2010) Pharmacotherapy , vol.30 , pp. 463-484
    • Neumiller, J.J.1    Wood, L.2    Campbell, R.K.3
  • 12
    • 65449151804 scopus 로고    scopus 로고
    • The scientific evidence: Vildagliptin and the benefits of islet enhancement
    • 1:CAS:528:DC%2BD1MXlvFOiuro%3D 19385979
    • Mathieu C. The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes Obes Metab. 2009;11 Suppl 2:9-17.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 9-17
    • Mathieu, C.1
  • 13
    • 84866645242 scopus 로고    scopus 로고
    • Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes
    • 1:CAS:528:DC%2BC38Xhs1Gks7%2FK 3447848 22688551
    • Rizzo MR, Barbiere MA, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes. Diabetes Care. 2012;35:2076-82.
    • (2012) Diabetes Care , vol.35 , pp. 2076-2082
    • Rizzo, M.R.1    Barbiere, M.A.2    Marfella, R.3    Paolisso, G.4
  • 14
    • 0033592101 scopus 로고    scopus 로고
    • Glucose tolerance and mortality: Comparison of WHO and American Diabetic Association diagnostic criteria
    • The DECODE study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet. 1999;354:617-21.
    • (1999) Lancet , vol.354 , pp. 617-621
  • 15
    • 0027490520 scopus 로고
    • Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women
    • 1:STN:280:DyaK2c%2FotVWgtA%3D%3D 1679451 8257886
    • Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ. 1993;307(6915):1318-22.
    • (1993) BMJ , vol.307 , Issue.6915 , pp. 1318-1322
    • Stensvold, I.1    Tverdal, A.2    Urdal, P.3    Graff-Iversen, S.4
  • 16
    • 0024538783 scopus 로고
    • Serum triglycerides as an independent risk factor for death from coronary heart disease in middle-aged Norwegian men
    • 1:STN:280:DyaL1M7jt1Ghtg%3D%3D 2916539
    • Tverdal A, Foss OP, Leren P, Holme I, Lund-Larsen PG, Bjartveit K. Serum triglycerides as an independent risk factor for death from coronary heart disease in middle-aged Norwegian men. Am J Epidemiol. 1989;129(3):458-65.
    • (1989) Am J Epidemiol , vol.129 , Issue.3 , pp. 458-465
    • Tverdal, A.1    Foss, O.P.2    Leren, P.3    Holme, I.4    Lund-Larsen, P.G.5    Bjartveit, K.6
  • 17
    • 0029741921 scopus 로고    scopus 로고
    • A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
    • 1:STN:280:DyaK28zns1Oltw%3D%3D 8782637
    • Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276(11):882-8.
    • (1996) JAMA , vol.276 , Issue.11 , pp. 882-888
    • Stampfer, M.J.1    Krauss, R.M.2    Ma, J.3    Blanche, P.J.4    Holl, L.G.5    Sacks, F.M.6
  • 18
    • 34447511196 scopus 로고    scopus 로고
    • Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
    • 1:CAS:528:DC%2BD2sXotVWmsrk%3D 17635890
    • Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299-308.
    • (2007) JAMA , vol.298 , Issue.3 , pp. 299-308
    • Nordestgaard, B.G.1    Benn, M.2    Schnohr, P.3    Tybjaerg-Hansen, A.4
  • 19
    • 56149115017 scopus 로고    scopus 로고
    • Nonfasting triglycerides and risk of ischemic stroke in the general population
    • 1:CAS:528:DC%2BD1cXhtlOrtb7J 19001625
    • Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008;300(18):2142-52.
    • (2008) JAMA , vol.300 , Issue.18 , pp. 2142-2152
    • Freiberg, J.J.1    Tybjaerg-Hansen, A.2    Jensen, J.S.3    Nordestgaard, B.G.4
  • 20
    • 0037992856 scopus 로고    scopus 로고
    • Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease
    • 12742806
    • Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med. 2003;163(9):1077-83.
    • (2003) Arch Intern Med , vol.163 , Issue.9 , pp. 1077-1083
    • Eberly, L.E.1    Stamler, J.2    Neaton, J.D.3
  • 21
    • 34447520136 scopus 로고    scopus 로고
    • Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
    • 1:CAS:528:DC%2BD2sXotValtb0%3D 17635891
    • Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309-16.
    • (2007) JAMA , vol.298 , Issue.3 , pp. 309-316
    • Bansal, S.1    Buring, J.E.2    Rifai, N.3    Mora, S.4    Sacks, F.M.5    Ridker, P.M.6
  • 22
    • 33746690405 scopus 로고    scopus 로고
    • Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
    • 1:CAS:528:DC%2BD28XnslSitbo%3D 16816950
    • Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, Dunning BE, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006;49(9):2049-57.
    • (2006) Diabetologia , vol.49 , Issue.9 , pp. 2049-2057
    • Matikainen, N.1    Manttari, S.2    Schweizer, A.3    Ulvestad, A.4    Mills, D.5    Dunning, B.E.6
  • 23
    • 55549136417 scopus 로고    scopus 로고
    • Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study
    • 1:CAS:528:DC%2BD1cXhsVKmt73K
    • DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. CurrMed Res Opin. 2008;24(10):2943-52.
    • (2008) CurrMed Res Opin , vol.24 , Issue.10 , pp. 2943-2952
    • DeFronzo, R.A.1    Okerson, T.2    Viswanathan, P.3    Guan, X.4    Holcombe, J.H.5    MacConell, L.6
  • 24
    • 77949273334 scopus 로고    scopus 로고
    • The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
    • 1:CAS:528:DC%2BC3cXhsVygt74%3D 19957161
    • Hsieh J, Longuet C, Baker C, Qin B, Federico L, Drucker D, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010;53(3):552-61.
    • (2010) Diabetologia , vol.53 , Issue.3 , pp. 552-561
    • Hsieh, J.1    Longuet, C.2    Baker, C.3    Qin, B.4    Federico, L.5    Drucker, D.6
  • 25
    • 79951933599 scopus 로고    scopus 로고
    • Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
    • 1:CAS:528:DC%2BC3MXktlylu7s%3D 21226820
    • Tremblay AJ, Lamarche B, Deacon CF, Weinagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:366-71.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 366-371
    • Tremblay, A.J.1    Lamarche, B.2    Deacon, C.F.3    Weinagel, S.J.4    Couture, P.5
  • 26
    • 84879030222 scopus 로고    scopus 로고
    • Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats
    • 1:CAS:528:DC%2BC3sXhtVajsb7I 3696328 23488656
    • Apaijai N, Pintana H, Chattipakorn SC, Chattipakorn N. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. Br J Pharmacol. 2013;169(5):1048-57.
    • (2013) Br J Pharmacol , vol.169 , Issue.5 , pp. 1048-1057
    • Apaijai, N.1    Pintana, H.2    Chattipakorn, S.C.3    Chattipakorn, N.4
  • 27
    • 33846827085 scopus 로고    scopus 로고
    • Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
    • 1:CAS:528:DC%2BD2sXjs1SrtL4%3D 17300593
    • Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175-85.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 175-185
    • Rosenstock, J.1    Kim, S.W.2    Baron, M.A.3    Camisasca, R.P.4    Cressier, F.5    Couturier, A.6
  • 28
    • 33847687205 scopus 로고    scopus 로고
    • Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
    • 1:CAS:528:DC%2BD2sXltVamt7w%3D 17373638
    • Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39:218-23.
    • (2007) Horm Metab Res , vol.39 , pp. 218-223
    • Dejager, S.1    Razac, S.2    Foley, J.E.3    Schweizer, A.4
  • 29
    • 34548118796 scopus 로고    scopus 로고
    • Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes
    • 1:CAS:528:DC%2BD2sXhtFejsb3L 17509069
    • Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med. 2007;24:955-61.
    • (2007) Diabet Med , vol.24 , pp. 955-961
    • Schweizer, A.1    Couturier, A.2    Foley, J.E.3    Dejager, S.4
  • 30
    • 77949356196 scopus 로고    scopus 로고
    • A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study
    • 1:CAS:528:DC%2BC3cXksl2ntL4%3D 20536495
    • Filozof C, Gautier J-F. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010;27(3):318-26.
    • (2010) Diabet Med , vol.27 , Issue.3 , pp. 318-326
    • Filozof, C.1    Gautier, J.-F.2
  • 31
    • 71849095372 scopus 로고    scopus 로고
    • Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drugnaive patients with type 2 diabetes
    • 1:CAS:528:DC%2BC3cXntFymsg%3D%3D 19705345
    • Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drugnaive patients with type 2 diabetes. Horm Metab Res. 2009;41(12):905-9.
    • (2009) Horm Metab Res , vol.41 , Issue.12 , pp. 905-909
    • Foley, J.E.1    Sreenan, S.2
  • 32
    • 58149330590 scopus 로고    scopus 로고
    • Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
    • 1:CAS:528:DC%2BD1MXivVWjtLk%3D 19125777
    • Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157-66.
    • (2009) Diabetes Obes Metab , vol.11 , Issue.2 , pp. 157-166
    • Ferrannini, E.1    Fonseca, V.2    Zinman, B.3    Matthews, D.4    Ahrén, B.5    Byiers, S.6
  • 33
    • 38149096290 scopus 로고    scopus 로고
    • Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
    • 1:CAS:528:DC%2BD1cXhs1ejtrg%3D 17947341
    • Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31(1):30-5.
    • (2008) Diabetes Care , vol.31 , Issue.1 , pp. 30-35
    • Rosenstock, J.1    Foley, J.E.2    Rendell, M.3    Landin-Olsson, M.4    Holst, J.J.5    Deacon, C.F.6
  • 34
    • 23844463766 scopus 로고    scopus 로고
    • Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
    • 1:CAS:528:DC%2BD2MXnvVWksL0%3D 15886245
    • Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(8):4888-94.
    • (2005) J Clin Endocrinol Metab , vol.90 , Issue.8 , pp. 4888-4894
    • Mari, A.1    Sallas, W.M.2    He, Y.L.3    Watson, C.4    Ligueros-Saylan, M.5    Dunning, B.E.6
  • 35
    • 67649908702 scopus 로고    scopus 로고
    • Antihyperglycaemic medication modifies factors of postprandial satiety in type 2 diabetes
    • 1:STN:280:DC%2BD1MvotVejsg%3D%3D 19476475
    • Mourad C, Chevalier S, Morais JA, Lamarche M, Gougeon R. Antihyperglycaemic medication modifies factors of postprandial satiety in type 2 diabetes. Diabetes Obes Metab. 2009;11(8):819-22.
    • (2009) Diabetes Obes Metab , vol.11 , Issue.8 , pp. 819-822
    • Mourad, C.1    Chevalier, S.2    Morais, J.A.3    Lamarche, M.4    Gougeon, R.5
  • 36
    • 84876847293 scopus 로고    scopus 로고
    • Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats
    • 23523961
    • Ávila Dde L, Araújo GR, Silva M, Miranda PH, Diniz MF, Pedrosa ML, et al. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats. Arch Med Res. 2013;44(3):194-202.
    • (2013) Arch Med Res , vol.44 , Issue.3 , pp. 194-202
    • Ávila Dde, L.1    Araújo, G.R.2    Silva, M.3    Miranda, P.H.4    Diniz, M.F.5    Pedrosa, M.L.6
  • 37
    • 84862027177 scopus 로고    scopus 로고
    • Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats
    • 22564388
    • Maeda S, Matsui T, Yamagishi S. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int J Cardiol. 2012;158(1):171-3.
    • (2012) Int J Cardiol , vol.158 , Issue.1 , pp. 171-173
    • Maeda, S.1    Matsui, T.2    Yamagishi, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.